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Objective: To evaluate the cost effectiveness of manual physiotherapy, exercise physiotherapy, and a
combination of these therapies for patients with osteoarthritis of the hip or knee.
Methods: 206 Adults who met the American College of Rheumatology criteria for hip or knee osteoar-
thritis were included in an economic evaluation from the perspectives of the New Zealand health system
and society alongside a randomized controlled trial. Resource use was collected using the Osteoarthritis
Costs and Consequences Questionnaire. Quality-adjusted life years (QALYs) were calculated using the
Short Form 6D. Willingness-to-pay threshold values were based on one to three times New Zealand’s
gross domestic product (GDP) per capita of NZ$ 29,149 (in 2009).
Results: All three treatment programmes resulted in incremental QALY gains relative to usual care. From
the perspective of the New Zealand health system, exercise therapy was the only treatment to result in
an incremental cost utility ratio under one time GDP per capita at NZ$ 26,400 ($34,081 to $103,899).
From the societal perspective manual therapy was cost saving relative to usual care for most scenarios
studied. Exercise therapy resulted in incremental cost utility ratios regarded as cost effective but was not
cost saving. For most scenarios combined therapy was not as cost effective as the two therapies alone.
Conclusions: In this study, exercise therapy and manual therapy were more cost effective than usual care
at policy relevant values of willingness-to-pay from both the perspective of the health system and
society.
Trial registration number Australian New Zealand Clinical Trials Registry ACTRN12608000130369.
 2013 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Hip and knee osteoarthritis (OA) are considered to be the most
serious musculoskeletal disorders from a public health view-
point1,2. OA is among the greatest causes of disability burden in
adults3, with signiﬁcant economic costs to individuals, healthcareto: J.H. Abbott, Centre for
f Surgical Sciences, Dunedin
Dunedin 9054, New Zealand.
bott).
s Research Society International. Psystems and society4. In 2009 OA was the fourth most frequent
primary diagnosis associated with hospital discharge5, and was the
most common diagnosis associated with 904,900 hip and knee
total joint arthroplasties performed in the US. Direct hospital costs
for these procedures were estimated to be $USD 42.3B.5
Multiple interventions exist for managing hip and knee OAwith
conservative treatments, primarily exercise therapy, recommended
as ﬁrst line treatments6. Zhang et al. suggested that referral to a
physiotherapist for instruction in exercise may be beneﬁcial7. A
recent systematic review of economic evaluations assessing con-
servative treatment in this patient population identiﬁed only two
studies investigating the cost effectiveness of exercise therapy8.
Both studies found group exercise to be highly cost effective, butublished by Elsevier Ltd. All rights reserved.
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estimate8. Although these results suggest exercise therapy may be
cost effective, neither investigated individualized, land-based ex-
ercise therapies8, a treatment method commonly used by physio-
therapists and considered to be the “ideal standard of clinical
practice”9. Manual therapy is another conservative intervention
used by physiotherapists that has shown promise for improving
pain and disability associated with hip10,11 and knee OA12,13. The
cost effectiveness of manual therapy has not been formally evalu-
ated, nor has the combination of manual therapy and exercise6.
We showed in the Management of Osteoarthritis (MOA) Trial
that manual physiotherapy and exercise physiotherapy are bene-
ﬁcial for people with OA.14 We now report an incremental cost
effectiveness and cost utility analysis of providing the three phys-
iotherapy treatments in addition to usual medical care, evaluated
from the perspectives of the New Zealand health system and
society15.
Methods
We conducted an economic evaluation alongside a 2  2
factorial randomized controlled trial for patients with knee or hip
OA carried out in New Zealand between April 2008 and April 2010
with a 1-year follow-up period. The MOA Trial compared manual
physiotherapy, exercise physiotherapy, and both treatments
together (i.e., combined manual therapy and exercise therapy) vs
usual medical care only15. The trial was registered on the Australian
New Zealand Clinical Trials Registry ACTRN12608000130369. We
published in advance the protocols for the randomized controlled
trial15 and the economic evaluation16.
Study population
Participants were recruited from two sources: (1) patients with
hip or knee OA attending general practitioners (GPs), and (2) pa-
tients referred to a hospital orthopaedic outpatient clinic to
consider hip or knee joint replacement surgery. To be eligible,
participants were required to meet the American College of
Rheumatology clinical criteria for hip or knee OA17,18. Participant
ﬂow is reported in our companion article14.
Randomization and blinding
After baseline assessment, participants were randomized using
an online randomization service that generated and held the
randomization schedule, ensuring allocation concealment.
Randomizationwas stratiﬁed by condition (hip or knee OA). Within
each stratum, participants were allocated to one of four groups:
usual care, exercise physiotherapy, manual physiotherapy, and
combined therapy. The block allocation size was subject to random
variation. Outcome assessors were blind to group allocation and
were not involved in providing the interventions. The orthopaedic
surgeons and GPs managing participants’ care were also blind to
group allocation.
Interventions
All participants continued to receive routine care offered by
their GP and other health care providers. The trial interventions
were delivered in a University of Otago community-based clinic
serving a population of 120,000. The MOA Trial interventions are
described elsewhere15,16. In brief, all treatments included a total of
nine 1-h treatments. Manual therapy focused on improving joint
mobility through manually administered forces to the target joint
and surrounding soft tissue. Exercise therapy focused on increasingstrength, neuromuscular control and ﬂexibility of the muscles of
the lower extremities. Combined therapy included both of these
interventions in each treatment session.Main outcome measures
The primary outcome for the MOA Trial was change in Western
Ontario and McMaster University osteoarthritis index (WOMAC)
score after 1 year14. The primary outcomes for the economic eval-
uation were quality-adjusted life years (QALYs) and total health
care costs related to OA for each intervention group compared with
usual care, expressed as incremental cost utility ratios (ICUR)16. We
estimated QALYs using the Medical Outcomes Study-Short Form 12
(SF-12v2)19, a 12-dimension instrument for measuring (generic)
health-related quality of life, which has been abridged to a six-
dimension instrument (SF-6D)20. The SF-6D applies utility
weights from the UK general population to estimate QALYs. We
calculated QALYs by using time-weighted averages at the beginning
and end of the 6-month and 1-year measurement periods. Costs
were reported from the perspectives of the New Zealand health
system and society.
We also considered changes in the number of participants
meeting the responder criteria of the Outcomes Measures in
Rheumatology Clinical TrialseOsteoarthritis Research Society In-
ternational (OMERACTeOARSI), which has been suggested as a
clinically relevant outcome in studies assessing the efﬁciency of
interventions for managing OA21.Resource use and valuation
We used the Osteoarthritis Cost and Consequences Question-
naire (OCC-Q) to collect data describing the costs and consequences
of hip and knee OA to the participants, their friends and families.
The OCC-Q has been validated for use in the New Zealand OA
population22. It was administered via patient interviews at the
baseline, 6-month and 1-year time points. Each participant was
asked to recall visits to health professionals, public and private
hospital use, medications, transportation costs, aids and adapta-
tions, and community service use for the preceding 3-month
period. Information about costs borne by participants’ friends or
family (out-of-pocket costs, transportation costs, lost earnings, and
informal care) was also collected.
The resource use data captured by the OCC-Q were valued using
unit costs derived from local and national sources (see Appendix 1).
All costs are expressed in 2009 New Zealand dollars (NZ$) exclusive
of government Goods and Services Tax (GST); in 2009 NZ$
1 y £0.43. For costs that needed to be adjusted for inﬂation, we
used the Organization for Economic Co-operation and Develop-
ment (OECD) price indices of gross domestic product (GDP) as
recommended by Welte et al.23. It was unnecessary to discount
costs and outcomes as the time horizon was just 1 year.
Annualized estimates for all cost items except for total joint
replacements and time off work were calculated by doubling
the estimates covering the two 3-month periods (obtained at the
6-month and 1-year follow-ups). Total joint replacements and the
associated time off workwere deemed to be items easily recalled by
participants at both follow-up points (a 6-month recall timeframe).
We veriﬁed total joint replacement surgery using the New Zealand
National Joint Register24. Time off work associated with OA, but not
as a result of surgery, was considered to be subject to a greater
degree of inaccuracy with respect to recall and was therefore
recalled over one month only25. Other cost items were assumed to
be constant over the baseline to 3-month and 6- to 9-month
periods.
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To quantify productivity losses we used the friction-cost
method, which counts productivity loss for the time it takes to
replace a worker26. We applied a 6-month friction period to a
participant’s loss of productivity during the MOA Trial. We calcu-
lated work-hour equivalents for the average number of hours
worked per day based on employment status. In New Zealand,
average full time employees work 8.7 h per day and average part
time employees work 4.6 h per day27. We applied individual
participant wage rates to time lost. As recommended, productivity
losses are reported separately28,29.
Statistical methods
Missing data
We chose to address both item-level missingness30 and
censored data31 via multiple imputation using the SAS IVEware
programme32. We treated data as ‘missing at random’, and imputed
missing components of the SF-12 and missing health care re-
sources. Data from participants who died during the trial were
treated as complete data with known costs and effects33. Five
imputed datasets were created.
The distribution of mean costs and effects between groups was
compared using the combined datasets (all ﬁve imputations com-
bined) and each individually imputed dataset. The descriptive
statistics of the fourth imputation matched those produced by the
combined datasets and was therefore chosen as the dataset for the
analysis. Mean differences between groups and 95% conﬁdence
intervals were obtained by bootstrap regressions (3,000 replica-
tions). We used generalized linear models (GLM) with baseline
values for each item. This type of model was chosen because it
maintains applicability to the sample mean cost regardless of the
scale from which costs are estimated34. Age, body mass index,
quadriceps muscle strength and self-efﬁcacy were added as cova-
riates for all comparisons of costs and outcomes after 1 year. To
match the model used in our companion article reporting clinical
effectiveness14 we added baseline pain intensity, duration since
ﬁrst diagnosis, mental health, joint with primary complaint of OA to
the model for outcomes after 1 year.
Cost utility analysis
To evaluate value for money we calculated estimates of ICURs
relative to usual care. Cost effectiveness acceptability curvesTable I




Men, no (% of group) 26 (51.0)
Women, no (% of group) 25 (49.0)
Age (years) 66.1 (10.7)
Body mass index (kg/m2) 29.5 (5.8)
Clinical
WOMAC score (range 0e240, lower scores represent less
pain and disability)
93.8 (52.8)
Duration since ﬁrst diagnosis of OA (years) 2.8 (1.3)
Pain intensity score (range 0e10, higher scores represent more pain) 3.1 (2.0)
Quadriceps muscle strength (kg/kg body mass) 0.21 (0.12)
Pain belief scoring instrument (PBSI) score (range 0e70, lower
scores indicate better self efﬁcacy)
29.3 (14.4)
Mental health (depression screening test) score indicates
low risk of depression, no (% of group)
26 (51.0)
Hip OA, no (% of group) 23 (45.1)
Knee OA, no (% of group) 28 (54.9)
Both hip and knee OA, no (% of group) 13 (25.5)(CEACs) were calculated for each treatment arm from the per-
spectives of the New Zealand health system and society. We fol-
lowed the World Health Organization recommendation to use
three threshold values in terms of GDP per capita for willingness to
pay (WTP) per QALY35. These thresholds for New Zealand in 2009
were: NZ$ 29,149 (1  GDP), NZ$ 58,298 (2  GDP) and NZ$ 87,447
(3  GDP). Cost effectiveness estimates were deﬁned as being
highly cost effective (<1  GDP), cost effective (1e3  GDP) or not
cost effective (>3  GDP)35.
Sensitivity analyses
The intention to treat (base case) analysis included imputed
missing and censored data. One-way sensitivity analyses were
conducted to assess the impact of important assumptions on the
cost effectiveness estimates:
(1) A pre-planned subgroup analysis was performed on partici-
pants who did not receive total joint replacement as a co-
intervention during the 1-year follow-up period.
(2) To evaluate the impact of imputation on the censored data,
only complete cases were assessed.
(3) To check the importance of the statistical model chosen for
analyzing effect data, a separate GLM was used to estimate
QALY gains.
(4) To investigate their impact on estimates, productivity losses
were excluded from the societal perspective.
Results
The characteristics of the 206 trial participants at baseline are
summarized in Table I. Aged between 37 and 92 years (mean 66
years), 45% of participants were wage earners, 55% female, and 98%
declared their ethnicity as New Zealand European. All participants
completed the OCC-Q and SF-12 questionnaires at baseline, 93.2%
at 6-months and 93.2% at 1 year. The dataset produced by the OCC-
Q questionnaire included 13% censored data. Although 15% of par-
ticipants had some data missing from the OCC-Q, missing items
comprised just 1% of the data overall.
Resource use
In the full sample, participants in the usual care group made
more visits to accident and emergency departments and to their GP
and rheumatologist, and received more meals onwheels and homeotherwise
control Manual therapy
alone (n ¼ 54)
Exercise therapy
alone (n ¼ 51)
Combined exercise þ
manual therapy (n ¼ 50)
26 (48.1) 19 (37.3) 21 (42.0)
28 (51.9) 32 (62.7) 29 (58.0)
67.3 (10.2) 66.9 (8.2) 66.0 (8.9)
29.2 (5.9) 29.3 (6.0) 30.1 (5.4)
114.8 (56.3) 95.5 (57.3) 99.1 (48.8)
2.5 (1.4) 2.6 (1.4) 2.9 (1.3)
4.2 (2.3) 3.5 (2.0) 4.0 (2.1)
0.20 (0.09) 0.20 (0.07) 0.20 (0.08)
29.4 (13.0 28.0 (13.7) 28.7 (11.9)
27 (50.9) 27 (52.9) 28 (56.0)
24 (44.4) 22 (43.1) 21 (42.0)
30 (55.6) 29 (56.9) 29 (58.0)
12 (22.2) 10 (19.6) 17 (34.0)
Table II
Resource use at 1 year for MOA Trial treatment groups. Values are mean (SD)









Joint procedures (no of procedures) 0.22 (0.50) 0.28 (0.53) 0.25 (0.52) 0.28 (0.50)
Orthopaedics (no of visits) 0.39 (0.60) 0.48 (0.72) 0.59 (0.85) 0.72 (1.01)
Rheumatology (no of visits) 0.10 (0.36) 0.02 (0.14) 0.02 (0.14) 0.02 (0.14)
Radiology (no of visits) 0.35 (0.74) 0.46 (0.75) 0.43 (0.67) 0.50 (0.74)
Accident and emergency (no of visits) 0.08 (0.27) 0.02 (0.14) 0.02 (0.14) 0.00 (0.00)
Community based services
GP (no of visits) 1.75 (1.74) 1.65 (1.56) 1.53 (1.87) 1.74 (1.48)
Repeat prescriptions (no of requests) 0.12 (0.43) 0.06 (0.23) 0.12 (0.43) 0.14 (0.40)
Practice nurse (no of visits) 0.12 (0.48) 0.13 (0.95) 0.06 (0.31) 0.12 (0.48)
Physiotherapy (no of visits) 0.75 (2.30) 0.78 (2.27) 1.31 (3.25) 1.26 (2.89)
Occupational therapy (no of visits) 0.12 (0.51) 0.13 (0.52) 0.04 (0.20) 0.26 (0.75)
Meals on wheels (no of meals) 3.00 (14.29) 2.96 (12.53) 0.00 (0.00) 1.20 (8.49)
Home help/house cleaning (no of visits) 4.20 (14.77) 3.59 (15.05) 3.98 (9.96) 2.40 (7.63)
Pharmaceuticals (no of capsules/tablets per day)
Paracetamol 2.55 (4.02) 4.42 (5.23) 3.87 (4.94) 3.74 (4.34)
Opioid analgesics 0.87 (2.64) 0.57 (1.62) 0.36 (1.20) 0.43 (1.40)
Paracetamol-opioid combined 1.19 (2.84) 0.16 (0.67) 0.14 (0.49) 1.34 (3.08)
NSAIDs 0.64 (1.42) 1.19 (2.44) 0.80 (1.81) 0.97 (1.42)
COX-2 0.18 (0.68) 0.04 (0.23) 0.00 (0.00) 0.08 (0.35)
Glucosamine & chondroitin 0.78 (1.3) 0.86 (1.27) 0.83 (1.16) 1.04 (1.36)
Omeprazole 0.50 (0.96) 0.35 (0.73) 0.45 (0.86) 0.49 (0.98)
Productivity loss (no of hours) 55.03 (133.19) 45.94 (178.77) 80.53 (262.77) 26.63 (81.10)
COX-2 ¼ cyclooxegenase II. NSAIDs ¼ non-steroidal anti-inﬂammatory drugs.
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They also had fewer joint procedures and made fewer visits to their
orthopaedist and physiotherapist (Table II).
Costs
From the perspective of the New Zealand health system, all
three treatments cost more than usual care (P < 0.05) regardless of
the sample analyzed (imputed sample, complete case) (Table III).
However, from the societal perspective, manual therapy cost less
than usual care under the base case and most sensitivity analyses.
From the societal perspective, exercise therapy cost more thanTable III
Costs (in 2009 NZ$) and health outcomes at 1 year in base case and sensitivity analyses.
Usual care Manual the
Cost outcomes (2009 NZ$)
MOA Trial programme 0 (0) 485.93 (2
Public health system costs 3,207.22 (7,160.24) 3,756.34 (6
Private health system costs 724.12 (3,457.348) 349.63 (2
Costs to patient, family, and friends
(transportation costs, copayments)
490.92 (638.97) 485.68 (4
Productivity costs 1,863.59 (5221.85) 1,053.30 (4
Total NZ health system costs 3,931.34 (7,649.30) 4,591.89 (6
Complete case 4145.92 (7,837.26) n ¼ 48 4,835.69 (6
No TJA during trial 678.70 (940.97) n ¼ 42 1,086.06 (7
Total societal costs 6,285.85 (9,908.92) 6,130.87 (8
Complete case 6,642.96 (10,109.94) n ¼ 48 6,448.19 (8
No productivity costs 4,422.26 (7,715.00) 5,077.57 (6
No TJA during trial 2,522.38 (4,600.38) n ¼ 42 1,691.24 (1
Health outcomes
QALYs 0.647 (0.067) 0.656 (0
QALYs, no TJA during trial 0.657 (0.067) 0.662 (0
QALYs, complete case 0.647 (0.067) 0.657 (0
WOMAC full score 80.90 (57.70) 73.33 (5
WOMAC physical function score 57.71 (42.69) 52.52 (4
WOMAC pain score 15.47 (12.01) 13.85 (1
OMERACTeOARSI responder
Percentage: 18/51 (37%) 31/54 (5
MOA ¼ Management of Osteoarthritis Trial intervention costs. NZ ¼ New Zealand. O
TrialseOsteoarthritis Research Society International responder criteria. TJA ¼ total joint
* The fourth imputed dataset was used for means (SD) except for the complete case vusual care under the base case and all sensitivity analyses. Com-
bined therapy cost less than usual care only in the case of partici-
pants who did not have joint replacement surgery during the trial.
From both perspectives, the differences between the total costs for
the three treatments were not statistically signiﬁcant (P > 0.05).
Effects
All three physiotherapy interventions produced statistically
signiﬁcant beneﬁts (P < 0.05) in terms of QALYs gained at 1 year
relative to usual care (seen in Fig. 1 as effects predominantly in
quadrants to the right of the y-axis). Exercise therapy produced the* Values are means (SD)
rapy Exercise therapy Combined therapy
05.99) 503.22 (187.26) 506.88 (189.08)
,139.33) 3,351.18 (6681.67) 2,138.55 (4,629.06)
,408.56) 731.57 (3,557.99) 2,319.80 (6,942.15)
96.21) 650.80 (921.90) 650.03 (641.26)
120.54) 1,600.73 (5285.90) 1,219.73 (5,938.64)
,362.79) 4,585.96 (72,43.95) 5,573.96 (8,066.56)
,466.63) n ¼ 51 4,833.78 (7,398.82) n ¼ 48 5,419.05 (8,115.93) n ¼ 45
43.32) n ¼ 41 1,037.74 (694.82) n ¼ 40 1,192.76 (1,213.24) n ¼ 37
,827.08) 6,837.49 (9,837.63) 7,565.08 (11,584.28)
,985.10) n ¼ 51 7,214.13 (10,023.56) n ¼ 48 7,235.22 (11,744.66) n ¼ 45
,438.11) 5,236.76 (7,585.39) 6,221.43 (8,166.83)
,154.76) n ¼ 41 2,737.08 (5,568.56) n ¼ 40 1,865.93(1,529.11) n ¼ 37
.062) 0.687 (0.064) 0.663 (0.062)
.065) 0.692 (0.067) 0.665 (0.067)
.061) 0.683 (0.064) 0.659 (0.061)
4.93) 66.25 (54.57) 71.74 (50.01)
1.45) 46.20 (38.44) 51.62 (36.85)
1.27) 13.43 (11.98) 13.26 (10.99)
9%) 26/51 (47%) 24/50 (52%)
MERACTeOARSI responder ¼ met Outcomes Measures in Rheumatology Clinical
arthroplasty.
alues for which the original dataset was used.
Fig. 1. Cost effectiveness plane and CEACs of the MOA physiotherapy treatments relative to usual care in terms of cost (in 2009 NZ$) per QALY gained from the perspectives of the
New Zealand health system and society for participants without joint replacement surgery during the trial (n ¼ 162) and all participants (n ¼ 206).
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more QALYs gained than combined therapy, this was not statisti-
cally signiﬁcant. Other measures of outcome effects are reported in
our clinical effectiveness article14.
Cost utility analyses
Of the three interventions evaluated, exercise therapy showed
the greatest likelihood of being cost effective from the perspective
of the New Zealand health system (Table IV and Fig. 1). At a mean
cost of NZ$ 26,400 per QALYgained, exercise therapy was below the
lowest WTP per QALY threshold adopted in this study (1  GDP per
capita). The probability of cost effectiveness was 53% and 95% at
WTP thresholds of 1 and 3  GDP per capita per QALY respectively
(Fig. 1). The probability that manual therapy was also cost effective
relative to usual care was above 50% (63%) at a WTP of 2  GDP per
capita and above 75% at 3  GDP per capita per QALY gained. From
the perspective of the New Zealand health system, combined
therapy was not cost effective for any WTP threshold considered in
this study.
From the societal perspective, manual therapy was cost saving
relative to usual care (lower cost and better health); however,
despite being better value for all WTP values, there was a large
degree of sampling uncertainty surrounding the estimate
(Table IV). Exercise therapy also performed well when considered
from the societal perspective; however, a lower probability of cost
effectiveness was reached (Fig. 1). From the societal perspective,
combined therapy produced an ICUR estimate of NZ$ 53,216;
however, the probability of combined therapy being more cost
effective relative to usual care at 3  GDP (NZ$ 87,447) was low
(Fig. 1).
Cost effectiveness analyses
In general, the clinically relevant outcome measures that were
assessed in the trial (improvements in the WOMAC score and cost
per additional OMERACTeOARSI responder gained) were associ-
ated with higher levels of cost effectiveness than usual care
(Table IV). Fig. 2 shows these outcomes plotted on cost effectivenessTable IV
Incremental cost utility and effectiveness ratios for manual therapy, exercise therapy, an
Manual therapy Exer
New Zealand health system perspective (base case)
QALYs 37,964 (80,990 to 430,801) 26,4
WOMAC index score 56 (223 to 323) [85%]
WOMAC function score 80 (491 to 747) [85%] 1
WOMAC pain score 265 (1,148 to 2,420) [85%] 6
OMERACTeOARSI responder 6,886 (10,383 to 75,259) [75%] 8,8
Sensitivity analyses
No TJA during trial 17,939 (2,668e345,856) 10,2
Complete case 35,371 (69,788 to 258,963) 31,5
QALYs (GLM) 39,668 (86,517 to 553,003) 27,2
Societal perspective (base case)
QALYs 38,072y (684,711 to 699,903) 23,3
WOMAC index score 89y (4,259 to 1,933) [85%]
WOMAC function score 129y (11,968 to 3,515) [85%]
WOMAC pain score 417y (27,953 to 10,581) [85%] 5
OMERACTeOARSI responder 6905y (267,237 to 53,526) [75%] 78
Sensitivity analyses
No TJA during trial 29,834y (644,387 to 75,294) 1
Complete case 32,723y (298,873 to 254,012) 31,3
No productivity losses 40,271 (78,468 to 452,666) 30,8
QALYs (GLM) 39,781y (791,497 to 830,269) 24,1
GLM ¼ generalized linear model, family (Gaussian), link (power 0.1).
* Values are incremental cost utility or cost effectiveness ratios (widest deﬁnable conﬁ
y Treatment dominates usual care, i.e., treatment costs less and is more effective thanplanes and CEACs. Unlike QALYs, there are no accepted threshold
values for the clinical outcomes; therefore we restricted our
consideration of cost effectiveness to a maximum threshold of NZ$
29,149 (1  GDP per capita). From the perspective of the New
Zealand health system and relative to usual care, the probability of
cost effectiveness reached 83% for both manual therapy and exer-
cise therapy per additional OMERACTeOARSI responder (Fig. 2).Sensitivity analyses
Subgroup with no joint replacement
When participants with a total joint replacement during the
trial were excluded from the analysis the signiﬁcant differences
between therapies remained as in the full sample with the excep-
tion that combined therapy no longer showed signiﬁcant
improvement in QALYs relative to usual care (seen in Fig. 1 as the
distribution representing combined therapy crossing the y-axis). In
addition, there was less variability in the cost estimates, as
demonstrated on the cost effectiveness plane (Fig. 1). From the
health system perspective all distributions were predominantly
above the x-axis, indicating higher costs for the treatment groups
relative to usual care (P < 0.05). For exercise therapy the ICUR was
NZ$ 10,217 per QALY, below the WTP threshold of 1  GDP per
capita. At a WTP of 1  GDP per capita (NZ$ 29,149) the probability
of cost effectiveness reached 99%. The ICUR for manual therapy
relative to usual care also fell below 1  GDP per capita, with its
probability of cost effectiveness relative to usual care reaching 75%
and 92% at 1 and 2GDP per capita respectively. The ICUR estimate
for combined therapy was NZ$ 47,702 (below 2  GDP per capita),
but the probability of cost effectiveness for this treatment relative
to usual care only reached 68% at the highest threshold considered
in this study (3 GDP). AtWTP values below NZ$ 10,217, usual care
was more cost effective than the treatment programmes. At
threshold levels below NZ$ 2,000 this difference was signiﬁcant
relative to all treatment programmes (Fig. 2).
From the societal perspective, manual therapy showed the
highest probability of being cost effective relative to usual care. This
was true for all WTP per QALY thresholds, ranging from 77% to 98%
for WTP thresholds of NZ$ 0 to NZ$ 87,447 per QALY (Fig. 1). Thed combined therapy relative to usual care (in 2009 NZ$)*
cise therapy Combined therapy
00 (34,081 to 103,899) 148,639 (31,041 to 7,934,188)
87 (233 to 6,037) [85%] 363 (65 to 203) [85%]
07 (169 to 554) [85%] 585 (107 to 206) [85%]
93 (36 to 23,896) [60%] 1,261 (191 to 1,539) [85%]
91 (10,875 to 148,629) [80%] 41,373 (7,986 to 10,952) [85%]
17 (2,401e23,628) 47,702 (4,688 to 50,545)
50 (35,988 to 114,870) 211,263 (13,376 to 13,894,893) [85%]
30 (35,208 to 108,392) 155,192 (1,350 to 1,375,368)
65 (102,356 to 163,958) 53,216 (860,844 to 1,115,191)
72 (16,229 to 7,602) [85%] 129 (1,898 to 3,357) [55%]
89 (1,428 to 1,419) [85%] 207 (3,822 to 11,867) [50%]
75 (2,544 to 4,289) [55%] 451 (9,579 to 16,493) [65%]
69 (67,654 to 156,133) [80%] 14,813 (19,7756 to 356,890) [45%]
63 (55,543 to 56,285) e 41,051y (1,346,311 to 113,497) [75%]
12 (223,693 to 295,806) 150,761 (6,963,719 to 7,649,696) [80%]
98 (30,717 to 110,669) 155,509 (22,376 to 8,143,496)
00 (105,870 to 170,840) 55,562 (1,410,040 to 1,968,810) [90%]
dence interval) [95% conﬁdence interval unless noted otherwise].
usual care.
Fig. 2. Cost effectiveness plane and CEACs of the MOA physiotherapy treatments relative to usual care in terms of cost (in 2009 NZ$) per OMERACTeOARSI responder gained from
the perspectives of the New Zealand health system and society for participants without joint replacement surgery during the trial (n ¼ 162) and all participants (n ¼ 206).
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usual care (>0.5 probability) regardless of the WTP threshold. For
exercise therapy, the probability of cost effectiveness relative to
usual care remained favourable; however, at very low WTP
thresholds (<NZ$ 150) manual therapy, combined therapy and
usual care appeared superior to exercise therapy. From the societal
perspective, combined therapy showed its highest level of cost
effectiveness in this subgroup with no replacement surgery during
the trial. In this analysis, combined therapy was cost saving relative
to usual care. The probability of cost effectiveness ranged from 68%
to 86% for WTP thresholds of NZ$ 0 to NZ$ 87,447 per QALY;
however, there was a large degree of sampling uncertainty sur-
rounding these estimates.
Other sensitivity analyses
In the complete case analysis the ICURs were higher across all
treatment groups relative to usual care, except for manual therapy
from the societal perspective, which remained cost saving. From
both cost perspectives, the ICUR for exercise therapy relative to
usual care shifted above the 1  GDP threshold, but remained
below the 2  GDP threshold. In this sensitivity analysis, from both
cost perspectives, ICUR estimates for combined therapy were
higher than all WTP threshold values considered in the study.
The exclusion of productivity losses from the analysis had its
greatest impact on the ICUR estimate of manual therapy. For every
other comparisonmanual therapy was cost saving from the societal
perspective; however, when productivity losses were excluded the
ICUR estimate showed lower levels of cost effectiveness (Table IV).
ICUR estimates for exercise therapy relative to usual care and
manual therapy relative to usual care were both below the 2  GDP
threshold.
There were no appreciable changes with respect to the ICURs as
a result of altering the construction of the regression model for the
effect estimate (Table IV).
Discussion
Providing either manual therapy or exercise therapy in addition
to usual care was highly cost effective relative to usual care alone
when considering the base case analyses from both cost perspec-
tives. Similarly, these treatments relative to usual care were asso-
ciated with estimates of ICURs that varied between being highly
cost effective and cost effective across all sensitivity analyses (i.e.,
estimates were between 1  GDP and 2  GDP). From the
perspective of the New Zealand health system, exercise therapy
was the most cost effective treatment: there were signiﬁcant im-
provements in QALYs and the cost effectiveness estimates were
distributed mostly in the northeast quadrant of the cost effective-
ness plane. From the societal perspective, manual therapy was
generally the most cost effective treatment: manual therapy was
cost saving compared with usual care, and this ﬁnding was robust
to most sensitivity analyses.
When considering the QALY as an outcome (in the full sample
and for participants without joint replacement surgery) therewas a
clear improvement in effect for exercise therapy relative to all other
treatments. The clinical trial showed a signiﬁcant antagonistic
interaction between the two interventions, manual therapy and
exercise therapy, with the combination generally less effective e or
at best no more effective e than either intervention alone14. As a
consequence of the signiﬁcant interaction effect, analysis of both
the clinical trial14 and this economic evaluation compared each of
the three physiotherapy interventions (in addition to usual care)
against usual care alone, rather than a factorial analysis of the main
effects of exercise therapy and manual therapy. The results of that
report14 are mirrored in both the costs and effects (QALY gains) inthis economic evaluation, although QALY gains (like physical per-
formance tests14, Table III) favoured exercise therapy over manual
therapy.
Comparison with previous studies
We are not aware of any previous economic studies assessing a
programme of manual physiotherapy for the treatment of hip or
knee OA. Two recent studies assessed the cost effectiveness of ex-
ercise programmes for the treatment of hip and/or knee OA36,37:
both investigated exercise therapy delivered via group sessions,
and both found cost savings. The probabilities of cost effectiveness
reported here are similar to those reported previously despite
including the additional cost of individual treatments with a
physiotherapist.
Implications for policy and recommendations
There is typically a long period of time between the initial
presentation to primary care with hip or knee complaints and the
need for joint replacement surgery; and during this time there is
low utilization of conservative therapies through primary care
management38e40. This period represents an opportunity to pre-
vent or delay the progression of pain and disability39,41,42, during
which time recommended treatments should be initiated. The su-
perior cost effectiveness of these treatments for participants in our
study without joint replacement suggests that conservative in-
terventions such as physiotherapy may be most cost-effective
during this period43. The reasons why conservative therapies are
under-utilized are manifold, but one reason may be a lack of
speciﬁcity in guideline recommendations as to content and de-
livery of these treatments. The exercise and manual therapy pro-
grammes used in the MOATrial have been shown to be beneﬁcial14,
and our detailed treatment protocols are now available. Our results
show that during this delay exercise therapy or manual therapy
(and to a lesser degree combined therapy) in addition to usual care
will provide good value for money for patients across the severity
spectrum.
Strengths and limitations of the study
This was a comprehensive economic evaluation set within a
randomized controlled trial with high levels of patient retention
(>93%) and robust methods to impute missing data32. The primary
data from the trial enabled the calculation of cost effectiveness
estimates using data with high internal validity44. The pragmatic
nature of the MOA Trial increases the generalizability of these
ﬁndings45. We used a cost data collection tool that captured a broad
range of costs and was validated for this purpose in the New Zea-
land OA population. Our sensitivity analyses tested the robustness
of our cost effectiveness estimates.
Our trial considered whether the interventions were more or
less effective when a common co-intervention was present33. From
the perspective of the New Zealand health system the physio-
therapy programmes demonstrated greater probabilities of cost
effectiveness relative to usual care for those with no joint
replacement surgery. This subgroup analysis was a particularly
important consideration in this study because joint replacement
surgery is known to be one of the most cost effective interventions
in this patient population46,47, and its inclusion in the intention to
treat analysis may have skewed the cost effectiveness estimates.
We have shown that the treatment programmes improved the
WOMAC index score and increased the numberofOMERACTeOARSI
responders relative to usual care14; however, it is difﬁcult to inter-
pret the value for money of these ﬁndings. Our results showed that,
D. Pinto et al. / Osteoarthritis and Cartilage 21 (2013) 1504e15131512from the societal perspective, the probability of cost effectiveness
formanual therapy perOMERACTeOARSI responderwas above70%,
even when societal valuations of an additional responder are zero.
This is a compelling ﬁnding, but it may be difﬁcult for decision
makers to interpret. It seems reasonable to conclude that high levels
of cost effectiveness at relatively low cost would be attractive to
decision makers. However, unless these beneﬁts can be tied to a
ﬁnal endpoint that is easier to value, it is questionablewhether they
will be considered by decision makers29.
Conclusions
The MOA Trial exercise physiotherapy and manual physio-
therapy programmes were cost effective relative to usual care
within policy relevant ranges of WTP per QALY from the perspec-
tives of the New Zealand health system and society.
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